ArticleJournal of thoracic disease2015
miR-1290 is a potential prognostic biomarker in non-small cell lung cancer.
Article in Journal of thoracic disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- A meta-analysis: microRNAs' prognostic function in patients with nonsmall cell lung cancer.Cancer medicine · 2017Pooled it
- An RNase domain-dependent microRNA detection with DNA-spiked nanocage for accurate cancer diagnosis.Nature communications · 2026Article
- 3D Nanofibrillar Matrix Stiffness Modulates Extracellular Vesicle Cargo and Pro-Tumour Functions.Journal of extracellular vesicles · 2025Article
- Article
- Circulating liver cancer stem cells and their stemness-associated MicroRNAs as diagnostic and prognostic biomarkers for viral hepatitis-induced liver cirrhosis and hepatocellular carcinoma.Non-coding RNA research · 2023Article
- CircSCN8A suppresses malignant progression and induces ferroptosis in non-small cell lung cancer by regulating miR-1290/ACSL4 axis.Cell cycle (Georgetown, Tex.) · 2023Article
- Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.Molecular biology reports · 2022Review
- An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.International journal of molecular sciences · 2022Review
- Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer.Oncology letters · 2021Article
- A Review on the Role of miR-1290 in Cell Proliferation, Apoptosis and Invasion.Frontiers in molecular biosciences · 2021Review
- Circulating miR-92b and miR-375 for monitoring the chemoresistance and prognosis of small cell lung cancer.Scientific reports · 2020Article
- Integrated Bioinformatics Analysis of mRNAs and miRNAs Identified Potential Biomarkers of Oral Squamous Cell Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- The Janus-like role of proline metabolism in cancer.Cell death discovery · 2020Review
- Novel Role for miR-1290 in Host Species Specificity of Influenza A Virus.Molecular therapy. Nucleic acids · 2019Article
- miR-1290 inhibits chordoma cell proliferation and invasion by targeting Robo1.Translational cancer research · 2019Article
- MicroRNA in Lung Cancer Metastasis.Cancers · 2019Review
- Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application.Journal of oncology · 2019Review
- Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.Journal of ovarian research · 2018Article
- miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B.Oncology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiR-1290 is a newly discovered microRNA (miRNA), and its role in non-small cell lung cancer (NSCLC) remains unknown. This study aimed to evaluate the expression levels of miR-1290 in NSCLC tissues and serum, and explore its associations with clinicopathological characteristics and prognosis of NSCLC patients.
methodsA total of 33 pairs of tissues and 73 serum samples were obtained from NSCLC patients and expression levels of miR-1290 were detected by specific TaqMan qRT-PCR. The relationship between miR-1290 expression levels in NSCLC tissues and serum and clinicopathological characteristics was estimated respectively. The correlation between serum miR-1290 expression levels and overall survival of NSCLC patients was performed by Kaplan-Meier analysis and Cox proportional hazards model.
resultsWe determined that miR-1290 expression levels were increased significantly in NSCLC tissues compared with non-tumor adjacent normal tissues, and higher miR-1290 expression levels were positively correlated with high tumor stage (P=0.004) and positive lymph node metastasis (P=0.013). Compared with benign lung disease and healthy controls, serum levels of NSCLC patients exhibited higher expression of miR-1290. Furthermore, the up-regulation of serum miR-1290 more frequently occurred in NSCLC patients with high TNM stage, positive lymph node metastasis (P=0.022 and P=0.024, respectively). Kaplan-Meier analysis demonstrated that high serum miR-1290 expression levels predicted poor survival (P=0.022). Cox proportional hazards risk analysis indicated that miR-1290 was an independent prognostic factor for NSCLC.
conclusionsOur study suggests that miR-1290 is overexpressed in NSCLC, and serum miR-1290 may be used as a potential prognostic biomarker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.